Hologic stock trades close to 52-week high as earnings growth supports valuation
Published on 08/29/2026 at 13:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Hologic stock is hovering close to its 52-week high as of August 28, 2026, with investors weighing earnings growth expectations against a premium valuation for the medical equipment provider (ISIN US4364401012).
Per a recent market overview dated August 28, 2026, the shares have traded in a 52-week range from $51.90 to $76.07, with the latest quote around $76.00 and a market capitalization of $16.97 billion, underscoring how far the stock has climbed from its lows over the past year. The stock carries a trailing price-earnings ratio of 31.67 based on trailing twelve month earnings per share of $2.40, reflecting a valuation that is above many traditional industrial names but below the broad market average.
Earnings profile and growth outlook
Hologic, Inc. is classified in the healthcare equipment and supplies industry, where consistent demand for diagnostics and surgical products helps underpin revenue stability but leaves earnings sensitive to procedure volumes and reimbursement dynamics. According to an earnings and valuation overview covering the latest reporting periods, earnings for Hologic are expected to grow by 7.94 percent in the coming year, with consensus figures pointing to a rise from $4.28 to $4.62 per share in the next full year.
The company calendar in that same overview lists the last reported earnings release on January 29, 2026, which corresponds to a recent quarterly result within the current fiscal year ending September 30, 2026. That quarterly update showed Hologic reporting earnings per share of $1.04, compared with analysts' consensus estimates of $1.09, meaning the company missed expectations by $0.05. While the earnings figure came in slightly below forecasts, revenue for the quarter grew 2.5 percent year over year, highlighting a modest top-line expansion even as margin dynamics limited EPS upside.
The gap between the reported $1.04 EPS and the $1.09 consensus illustrates how sensitive the stock can be to relatively small deviations from expectations. A miss of $0.05 per share on quarterly earnings may not be large in absolute terms, but for a company trading at a trailing price-earnings ratio of 31.67, even such incremental shortfalls are closely watched by investors assessing whether the valuation can be sustained by future profit growth.
Valuation, price targets and trading range
In the latest compiled analyst data, the average price target for Hologic stands at $79.13 per share, with estimates spanning a high target of $90.00 and a low target of $76.00. With the current share price near $76.00 as of August 28, 2026, the consensus target implies upside of 4.1 percent from present levels, suggesting that analysts see limited but positive appreciation potential over the next 12 months if earnings follow forecast trajectories.
The 52-week range from $51.90 to $76.07 places the current quote essentially at the top end of its annual band, underscoring the extent of the stock's recovery from its lows. From the bottom of $51.90 to the current $76 level, Hologic shares have advanced more than $24 in absolute terms, equating to a gain of well over 40 percent over that period. Against that price move, the market capitalization of $16.97 billion as reported in the latest overview positions Hologic firmly in the mid-cap segment of the healthcare equipment space, where competition for capital allocation often hinges on relative growth and profitability metrics.
With trailing twelve month earnings per share at $2.40 and a trailing price-earnings ratio of 31.67, investors are paying a substantial multiple for the company’s earnings base. The forward price-earnings ratio of 17.76, however, points to a material compression in valuation if forecasted EPS of $4.62 materializes over the coming year. The spread between the trailing and forward multiples reflects the fact that analysts expect earnings to expand substantially, and the market has already priced in part of that anticipated improvement.
Profitability and margins in context
Hologic's profitability metrics as of the latest reporting period show net income of $565.70 million and net margins of 13.18 percent, figures that align with the economics of specialized medical equipment where research and development, regulatory compliance and sales infrastructure impose meaningful costs. A net margin in the low teens suggests that the company is able to convert a significant proportion of its revenue into bottom-line profit, though not at the levels seen in some high-margin software or patent-heavy pharmaceutical businesses.
Given the net income figure of $565.70 million, the implied revenue base for Hologic reaches into the multi-billion dollar range, reflecting broad adoption of its diagnostics and surgical products across hospitals, clinics and laboratories. The earnings profile benefits from recurring demand for test kits, imaging systems and related consumables, which can smooth revenue over time even as macroeconomic cycles and healthcare budgets fluctuate.
The trailing earnings per share of $2.40, when set against the expected EPS increase to $4.62, highlights the strong earnings growth embedded in consensus forecasts. If Hologic achieves that progression, shareholders would see earnings nearly double relative to the trailing base, supporting the forward price-earnings multiple of 17.76 and potentially justifying the consensus price target of $79.13. At the same time, the recent EPS miss versus consensus points to execution risk, reminding investors that delivering on elevated expectations requires continued operational discipline and product momentum.
Business model anchored in diagnostics and surgery
Hologic, Inc. has built its business around medical equipment and diagnostic solutions, particularly in areas such as women's health, breast imaging, gynecologic surgery and infectious disease diagnostics. Its portfolio includes imaging systems, surgical devices and diagnostic platforms that are used in hospitals and clinics worldwide to detect disease, guide procedures and monitor patient health. Revenue streams typically combine capital equipment sales with ongoing consumables and service contracts, creating a mix of one-time and recurring income.
The company competes in segments where technological innovation, clinical evidence and reliability are crucial. For example, in breast imaging and mammography, providers demand high-resolution imaging, low radiation doses and robust reliability, making research and development investment central to maintaining competitive advantage. In diagnostics, assay performance, throughput and ease of use influence adoption, while regulatory approvals govern market access.
Hologic's strategy has often emphasized expanding its installed base of diagnostic instruments and imaging systems, then driving recurring revenue through consumables and service agreements. Such a model can increase earnings visibility, as each installed instrument generates demand for test cartridges, reagents or maintenance services over many years. For investors, that recurring component may help explain why the market is comfortable assigning a premium valuation multiple relative to some peers with more transactional revenue patterns.
Analyst expectations and consensus dynamics
The consensus analyst view, as reflected in the compiled data for Hologic, classifies the stock with a hold rating and an average rating score of 2.00 on a zero-to-four scale. That stance signals that, on balance, analysts see neither compelling undervaluation nor severe overvaluation at current levels, but rather a stock whose future performance is likely to track fundamental earnings delivery. The coverage includes 12 analysts, providing a reasonably diverse set of opinions while avoiding overconcentration in any single viewpoint.
Within that framework, the price target range from $76.00 to $90.00 delineates differing perspectives on the degree of upside potential. The low target at $76.00 suggests that some analysts view the stock as fairly valued around the current price, whereas the high target at $90.00 implies room for additional appreciation if Hologic continues to execute on its growth strategy and potentially exceeds earnings expectations. For investors, the spread between low and high targets underscores the importance of monitoring upcoming earnings releases and product developments that could shift sentiment.
The expected earnings growth of 7.94 percent in the coming year, moving EPS from $4.28 to $4.62, sits at the heart of those valuations. If the company reports figures in line with or above this trajectory, the forward multiples may prove conservative. Conversely, if earnings growth slows or guidance is revised downward, the present premium could compress, leading to a reassessment of price targets and ratings.
Recent quarterly performance and revenue trends
The quarterly report released on January 29, 2026, provides insight into how Hologic is performing in the current fiscal year. The $1.04 earnings per share figure, while short of the $1.09 consensus by $0.05, still demonstrates solid profitability and reinforces the company’s ability to generate substantial earnings from its medical equipment operations. The 2.5 percent year-over-year revenue growth in that quarter is more modest but points to ongoing demand, particularly in core diagnostics and surgical segments.
Such incremental revenue increase may reflect a mix of volume growth, pricing dynamics and product mix shifts. In healthcare equipment, incremental gains can stem from expanded adoption of new products, increased utilization of existing devices and successful cross-selling of consumables and services. Even a few percentage points of top-line growth, when combined with operational efficiency, can yield meaningful earnings expansion over time.
The quarterly miss versus expectations also provides a benchmark for future performance. If subsequent quarters in fiscal 2026 show faster revenue growth or improved margins, the January 29, 2026 result may be viewed as a temporary pause in a broader upward trend. However, if growth remains constrained or expenses rise faster than revenue, consensus forecasts for EPS progression to $4.62 could face downward revision, affecting the stock's forward valuation metrics.
Competitive positioning in healthcare equipment
Within the healthcare equipment and supplies industry, Hologic stands out for its focus on diagnostic and surgical solutions that are deeply integrated into clinical workflows. While the broader sector includes a wide range of companies from imaging and monitoring device makers to orthopedic implant manufacturers, Hologic’s emphasis on women's health, breast imaging and diagnostic platforms positions it in niches where clinical guidelines and screening programs drive steady demand.
The company’s net margin of 13.18 percent suggests that it competes effectively in these segments, maintaining profitability while investing in research and development and navigating regulatory requirements. Profitability levels in the low-to-mid teens are common among specialized medtech companies that balance high-value products with substantial fixed costs associated with innovation, regulatory compliance and sales infrastructure.
As of the latest data, Hologic employs 7,070 people, supporting its global operations across manufacturing, research, sales and support. This workforce size reflects the scale required to serve healthcare providers worldwide and maintain the installed base of imaging systems and diagnostic platforms. For investors, the combination of a sizable employee base, multi-billion dollar revenue and mid-teens margins paints a picture of a mature, established medtech company rather than a small, high-risk startup.
Representative product focus
Among Hologic's notable offerings are advanced diagnostic and imaging systems used in breast health and women's health more broadly. These systems are designed to deliver high-quality images, support early detection of disease and integrate seamlessly with clinical workflows. Many of the company’s platforms pair with proprietary consumables and software, ensuring that once a system is installed at a hospital or clinic, ongoing revenue is generated through cartridges, reagents, service contracts and software updates.
The success of such products depends on continuous innovation and clinical validation. Healthcare providers evaluate imaging and diagnostic systems based on sensitivity, specificity, throughput and ease of use, seeking platforms that improve patient outcomes and operational efficiency. Hologic's commitment to research and development aims to sustain performance leadership in these metrics, reinforcing the recurring revenue model tied to its installed base.
Stock trading context as of late August 2026
As of August 28, 2026, Hologic stock trades on the Nasdaq exchange under the symbol HOLX, with its latest price near $76.00 and a 52-week high of $76.07. With a market capitalization of $16.97 billion and a trailing price-earnings ratio of 31.67, the shares reflect investor confidence in the company’s earnings growth potential and the resilience of its healthcare equipment franchise. At the same time, the limited upside implied by the average price target of $79.13 signals that much of the near-term optimism may already be embedded in the price.
For investors assessing Hologic stock at the end of August 2026, the key numerical markers are clear: a 52-week range from $51.90 to $76.07, trailing twelve month earnings per share of $2.40, net income of $565.70 million, net margin of 13.18 percent, expected EPS growth from $4.28 to $4.62 representing a 7.94 percent increase and a forward price-earnings ratio of 17.76. Together, these figures frame a story of a mid-cap healthcare equipment company with solid profitability, meaningful earnings growth expectations and a valuation that balances current earnings strength against future expansion prospects.
Go deeper
Read-more coverage on Hologic stock often highlights the interplay between diagnostics demand, surgical volumes and earnings trajectories, as well as the way consensus targets evolve after each quarterly report.
Investor Relations
Additional company information, including product details and regulatory disclosures, is available through Hologic's own investor communications.
Hologic product snapshot
A representative example of Hologic's product profile is its advanced breast imaging system line, designed to support early detection of breast cancer and improve diagnostic accuracy. These systems often incorporate digital imaging technology, ergonomic design for patient comfort and software tools that assist radiologists in interpreting scans. When combined with high throughput and integrated data management, such platforms can become central to a hospital’s breast health program, supporting regular screening and diagnostic follow-up.
Closing view on Hologic stock
As of August 28, 2026, Hologic stock trades on Nasdaq around $76.00, close to its 52-week high of $76.07, with a market capitalization of $16.97 billion and valuation metrics that hinge on delivering expected earnings growth from $4.28 to $4.62 per share over the coming year.
Fact box
Company: Hologic, Inc.
ISIN: US4364401012
Ticker: HOLX
Exchange: Nasdaq
Price (as of August 28, 2026): $76.00 USD
Market cap: $16.97 billion (as of August 28, 2026)
Sector / Industry: Healthcare equipment and supplies
Index membership: Nasdaq composite
